CeriBell (NASDAQ:CBLL) VP David Foehr Sells 9,255 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 9,255 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $24.25, for a total value of $224,433.75. Following the sale, the vice president owned 34,144 shares of the company’s stock, valued at approximately $827,992. This represents a 21.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

David Foehr also recently made the following trade(s):

• On Monday, August 24th, David Foehr sold 859 shares of CeriBell stock. The stock was sold at an average price of $23.95, for a total transaction of $20,573.05.
• On Friday, August 21st, David Foehr sold 993 shares of CeriBell stock. The stock was sold at an average price of $24.02, for a total transaction of $23,851.86.

CeriBell Stock Performance

Shares of NASDAQ CBLL opened at $23.43 on Friday. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $25.33. The firm has a market capitalization of $899.24 million, a price-to-earnings ratio of -13.31 and a beta of 0.95. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16. The firm has a 50 day moving average of $21.03 and a 200 day moving average of $19.61.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%.The business had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. On average, research analysts anticipate that CeriBell, Inc. will post -1.96 earnings per share for the current year.

Institutional Trading of CeriBell

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC bought a new position in CeriBell in the 2nd quarter worth approximately $638,000. California State Teachers Retirement System raised its position in shares of CeriBell by 409.5% during the second quarter. California State Teachers Retirement System now owns 7,352 shares of the company’s stock valued at $143,000 after buying an additional 5,909 shares during the last quarter. Wellington Management Group LLP raised its position in shares of CeriBell by 5.5% during the second quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock valued at $1,706,000 after buying an additional 4,572 shares during the last quarter. Formula Growth Ltd. purchased a new position in shares of CeriBell in the second quarter worth $603,000. Finally, Bank of America Corp DE bought a new position in shares of CeriBell during the second quarter worth $4,619,000.

Wall Street Analyst Weigh In

Several research firms have recently commented on CBLL. Barclays raised CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Raymond James Financial reiterated a “strong-buy” rating and set a $29.00 price objective on shares of CeriBell in a research note on Thursday, September 3rd. BTIG Research increased their target price on shares of CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Weiss Ratings cut shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 28th. Finally, Canaccord Genuity Group upped their price target on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and an average target price of $24.40.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.